This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse).
This trial is recruiting in multiple locations in New York and New Jersey, US.
Stereotactic body radiation therapy (SBRT) is a non-invasive cancer treatment. It uses radiation waves to target cancer cells and kill them. The radiation beams are given from multiple angles and they meet on the tumor. SBRT is very useful in patients with inoperable cancer. It can also be useful in patients with secondary tumors. Secondary tumors are called metastases (MTs). Metastatic cancer (MTC) can be more difficult to treat due to the various locations.
This trial will investigate if SBRT can delay tumor getting worse in patients with metastatic cancer. The main outcome will be PFS.
Who are they looking for?
This study will recruit 142 participants with MTC. Patients with triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC) will be recruited. Patients with brain MTs can take part if they have been treated. Adequate organ function is also essential for SBRT.
Patients cannot take part in the trial if they are pregnant or breastfeeding or if they have another cancer. Patients cannot take part if the trial interferes with their planned treatment protocol. Patients with liquid in the lung or abdomen will be excluded.
How will it work
Patients will be assigned to one of 2 groups. One group will receive standard treatment (ST). This could include targeted drugs, hormones, immunotherapy or chemotherapy. The second group will receive ST and SBRT. The study will last up to 2 years.